Understanding maternal immune responses affecting newborns with low platelet counts
Official title: Interrogating clinically relevant attributes of maternal alloimmunity in fetal/neonatal alloimmune thrombocytopenia
Funded at Versiti Wisconsin, INC. · NIH-11079524 · Data updated 2026-11-12
This study is looking at how a mother's immune system can affect her baby's platelets, which might lead to a serious bleeding condition in newborns, and it aims to find out which pregnancies are at higher risk so that better tests and prevention methods can be developed to help keep babies safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Wisconsin, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $420,866 |
| NIH project number | 5R01HL169144-02 |
| Project ID | NIH-11079524 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include pregnant women who have previously had a child affected by fetal/neonatal alloimmune thrombocytopenia or those identified as at-risk for this condition.
✕Less likely to help
Patients who are not pregnant or those whose pregnancies are not at risk for fetal/neonatal alloimmune thrombocytopenia may not benefit from this research.
What this research studies
This research investigates how maternal immune responses to specific platelet proteins can lead to a serious condition in newborns called fetal/neonatal alloimmune thrombocytopenia (FNAIT). It aims to identify which pregnancies are at high risk for severe bleeding due to this condition by studying the interactions between maternal antibodies and fetal platelets. The research will utilize animal models to explore the underlying mechanisms and develop potential diagnostic tests and preventive strategies. By understanding these immune responses better, the research seeks to improve outcomes for affected infants.
Why it matters
Potential benefit: If successful, this research could lead to better identification and management of at-risk pregnancies, potentially preventing severe bleeding and associated complications in newborns.
How similar studies have gone: While the specific approach of this research is novel, similar studies have shown promise in understanding immune responses in pregnancy and their effects on newborn health.
Where this research is happening
-
Versiti Wisconsin, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Newman, Debra Kay — Versiti Wisconsin, INC.
- Study coordinator: Newman, Debra Kay
Related research
Other NIH-funded projects on the same topics.
-
New ideas to understand, diagnose, and treat heparin-induced thrombocytopenia
A Mayo Clinic led study will look at the different kinds of HIT antibodies to improve diagnosis and treatment for people with HIT.
-
Second-generation BLVRB inhibitors to help chemotherapy patients with low platelets
A new drug candidate is being developed to raise platelet counts in patients whose cancer treatment lowers them, reducing bleeding risk.
-
Immunobiology of vaccine-related clotting after adenovirus vaccines
This research asks how antibodies linked to a rare vaccine-related clotting condition (VITT) interact with specific blood proteins to cause clots after certain COVID-19 vaccines.
-
Understanding and diagnosing Heparin-Induced Thrombocytopenia (HIT)
A project to understand the immune factors behind HIT and develop faster, more accurate tests to help people who need heparin therapy.
-
Fetal and neonatal platelet allergy: understanding why some babies bleed
A study to understand why maternal antibodies cause serious bleeding in babies with FNAIT, using an animal model and human-relevant clues to improve future care for affected families.
-
Molecular mechanisms behind immune-related low platelets and clots in transfusion medicine
This grant supports a team of researchers to understand how immune factors cause low platelets and abnormal clots, with a focus on transfusion medicine and pediatric to adult patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.